NMN Holdings LP

NEW YORK, NY · Founded 2018 · CIK 0001756135 · Biotech

NAD+ precursor nicotinamide mononucleotide (NMN) research platform and longevity intervention development

nmn.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
1 Form D · Oct 2018
96 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1825Prairie Pharms, LLC—$455K
1826Magna Pharmaceuticals, Inc.—$1.0M
1827CanaQuest Medical Corp.—$31K
1828NMN Holdings LP——
1829Reven Pharmaceuticals, Inc.—$23K
1830Harton, Inc.—$15M
1831SciTech Development, Inc.—$470K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Barbara BurnsExecutive Officer
  • Steven DeCillisExecutive Officer
  • J. LevengoodDirector · Executive Officer
  • Thomas PrymaDirector · Executive Officer
  • J. SharpeDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.